Legal Representation
Attorney
ROGER H. BORA
USPTO Deadlines
Next Deadline
1870 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250218)
Due Date
February 18, 2031
Grace Period Ends
August 18, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
49 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 18, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Feb 18, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jan 27, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Jan 27, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Jan 24, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 24, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 24, 2025 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jan 13, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 13, 2025 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Jan 13, 2025 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Oct 15, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 15, 2024 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 15, 2024 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Jun 15, 2024 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| May 13, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Jun 15, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| May 13, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| May 11, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 10, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 10, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| May 10, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 14, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 20, 2023 | EXPT | T | EXPARTE APPEAL TERMINATED | Loading... |
| Oct 19, 2023 | EXPT | T | EXPARTE APPEAL TERMINATED | Loading... |
| Oct 19, 2023 | EXDM | T | EXPARTE APPEAL DISMISSED AS MOOT | Loading... |
| Sep 19, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 19, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 30, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 15, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 8, 2023 | EXPI | T | EX PARTE APPEAL-INSTITUTED | Loading... |
| Aug 8, 2023 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY | Loading... |
| Aug 8, 2023 | EXAF | T | EXPARTE APPEAL RECEIVED AT TTAB | Loading... |
| Aug 3, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 3, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 3, 2023 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Apr 27, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Apr 27, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Feb 10, 2023 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Feb 10, 2023 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Feb 10, 2023 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Jan 4, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jan 4, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jan 4, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 5, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 5, 2022 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 5, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 15, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 8, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 28, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of blood samples for the purpose of drug development by others, namely, data-driven analytics and reporting to developers of drugs; scientific and technological services in the field of pharmaceuticals featuring scientific testing, analysis and evaluation of blood samples for the purpose of improving quality in the field of healthcare services, specifically for improving the monitoring and diagnostics of quantitative patient drug exposure, the monitoring and diagnostics of patient drug compliance, data-driven analytics and reporting to providers of healthcare services in the field of pharmacovigilance activities, drug dosage recommendations, initial drug prescribing, and drug switching, all for research purposes and not for medical purposes; genetic testing for scientific research purposes, specifically pharmacogenomic testing, analysis, and evaluation of buccal, saliva and other biological samples for the purposes of analyzing how the genetic makeup of an individual affects their response to drugs, improving drug selection and dosage recommendations, selecting initial and subsequent medications, identifying drug-drug interactions, avoiding adverse drug reactions, developing clinical treatment decision support recommendations, and supporting other medical diagnostic products and prescription drugs; genetic testing for scientific research purposes, namely, analysis of multiple genes and genetic variants and their effect on drug response across multiple therapeutic areas, including but not limited to psychiatry, pain, cardiology, and oncology; scientific and technological services in the field of pharmaceuticals in the nature of scientific testing, analysis and evaluation of biological samples for research purposes, specifically research in the field of clinical trials, and research in the field of new drug development and drug repurposing
First Use Anywhere:
20230200
First Use in Commerce:
20230200
Additional Information
Pseudo Mark
PREDICT SCRIPT
Classification
International Classes
042